Sugi Predict

Sugi Predict / Compounds / SCHEMBL10142446

SCHEMBL10142446

SCHEMBL10142446

Cc1ccc(N2CCC(C)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.59
▸ ADRB1 P08588 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MEN1 O00255 5/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ MAPT P10636 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ GPR119 Q8TDV5 1/20 0.46
▸ TSHR P16473 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ L3MBTL3 Q96JM7 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NPC1 O15118 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19314278 0.88 USP2 (0.47) USP2ADRB1ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL23542992 0.85 EBP (0.60) USP2ADRB1ALDH1A1CYP1A2MEN1
SCHEMBL15189519 0.83 GPR119 (0.58) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL22537505 0.83 ADRB1 (0.55) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL22940344 0.81 KMT2A (0.64) USP2ADRB1MEN1KMT2AL3MBTL3
SCHEMBL10063748 0.81 ADRB1 (0.70) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL7105773 0.81 ADRB1 (0.70) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL3414344 0.81 ADRB1 (0.70) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL22537904 0.81 ADRB1 (0.53) USP2ADRB1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6287835 0.81 MAPT (0.59) USP2ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024054591-A1 RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-03-14 — — WO disclosed
WO-2022167867-A1 SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2022-08-11 — — WO disclosed
WO-2022068933-A1 COMPOUNDS AND METHODS OF TREATING DISEASES CULLGEN (SHANGHAI) , INC. (CN) 2022-04-07 — — WO disclosed
WO-2021229359-A2 PROCESS FOR THE PREPARATION SALTS OF TRIAZOLE COMPOUNDS CELLIX BIO PRIVATE LIMITED (IN) 2021-11-18 — — WO disclosed
WO-2021125329-A1 RADICAL GENERATION FILM-FORMING COMPOSITION, RADICAL GENERATION FILM, AND METHOD FOR MANUFACTURING HORIZONTAL-ELECTRIC-FIELD LIQUID CRYSTAL CELL 日産化学株式会社 2021-06-24 — — WO disclosed
US-10907101-B2 Liquid crystal cell and liquid crystal display SHARP KABUSHIKI KAISHA (JP) 2021-02-02 — — US disclosed
WO-2021003314-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2021-01-07 — — WO disclosed
WO-2020210383-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-10-15 — — WO disclosed
WO-2020210377-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-10-15 — — WO disclosed
US-10761375-B2 Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2020-09-01 — — US disclosed
US-8822444-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-02 — — US disclosed
US-8785487-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-07-22 — — US disclosed
US-20120076755-A1 Hepatitis C Virus Inhibitors ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-20120039848-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2012-02-16 — — US disclosed
EP-1846366-B1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-03 — — EP disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 — — US disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 — — US disclosed
WO-2008103351-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2008-08-28 — — WO disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 — — US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039848-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 USP2 2741/4885ADRB1 3134/4885ALDH1A1 365/4885
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof SLC38A7, SLC7A1, SLC6A7 USP2 2942/4885ADRB1 176/4885ALDH1A1 2442/4885
US-20120076755-A1 Hepatitis C Virus Inhibitors NSUN2, HCCS, HAVCR2 USP2 3095/4885ADRB1 2394/4885ALDH1A1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.